Email: info@neweastbio.com   |  Call: 6109452007

F5(Coagulation factor V heavy chain) Rabbit pAb

Anti-F5(Coagulation factor V heavy chain) Rabbit Polyclonal Antibody
5/5

$349.00

Cat.#:  S215769

   Size:   100 μl

In Stock

            Product Description          
Cat.#:   S215769
Product Name:   Anti-F5(Coagulation factor V heavy chain) Rabbit Polyclonal Antibody
Synonyms:   FVL; PCCF; THPH2; RPRGL1
UNIPROT ID:   P12259 (Gene Accession – NP_000121 )
Background:    This gene encodes an essential cofactor of the blood coagulation cascade. This factor circulates in plasma, and is converted to the active form by the release of the activation peptide by thrombin during coagulation. This generates a heavy chain and a light chain which are held together by calcium ions. The activated protein is a cofactor that participates with activated coagulation factor X to activate prothrombin to thrombin. Defects in this gene result in either an autosomal recessive hemorrhagic diathesis or an autosomal dominant form of thrombophilia, which is known as activated protein C resistance.
Immunogen:    Synthetic peptide of human F5(Coagulation factor V heavy chain)
Applications:    ELISA, IHC
Recommended Dilutions:    IHC: 20-100; ELISA: 2000-5000
Host Species:    Rabbit
Clonality:    Rabbit Polyclonal
Isotype:    Immunogen-specific rabbit IgG
Purification:    Antigen affinity purification
Species Reactivity:    Human, Mouse
Constituents:    PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol
Research Areas:    Cardiovascular
Storage & Shipping:    Store at -20°C. Avoid repeated freezing and thawing

Immunohistochemistry analysis of paraffin embedded Human cervical cancer tissue using 215769(F5(Coagulation factor V heavy chain) Antibody) at a dilution of 1/20(Secreted).

In comparision with the IHC on the left, the same paraffin-embedded Human cervical cancer tissue is first treated with the synthetic peptide and then with 215769(Anti-F5(Anti-Coagulation factor V heavy chain) Antibody) at dilution 1/20.
          Publications